ZEN003694

Phase 2Small molecule

ZZenith Epigenetics

ZEN003694 is one of 97 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adriamycin

GGynecologic Oncology Group

Preclinical

87 2

Avastin

ZEN003694

1 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

Voltaren

Novartis

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Vfend

PPrism Pharmaceuticals

Systemic Therapy

1 10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Lung Cancer

NCT05607108

Q1 2033

Phase 2Recruiting

Ovarian Cancer

NCT05071937

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·ZZenith Epigenetics·Phase 1/2·NCT02711956·75 enrolled

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·ZZenith Epigenetics·Phase 1·NCT02705469·44 enrolled

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Recruiting·ZZenith Epigenetics·Phase 2·NCT04986423·200 enrolled

Lung Cancer1 trial

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05607108·13 enrolled

Ovarian Cancer1 trial

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Recruiting·—·Phase 2·NCT05071937·33 enrolled

Breast Cancer1 trial

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

Terminated·ZZenith Epigenetics·Phase 2·NCT03901469·115 enrolled

Solid Tumors1 trial

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Withdrawn·HHaider Mahdi·Phase 1·NCT06161493

1 more indication

Unspecified1 trial

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Enrolling by invitation·ZZenith Epigenetics·Phase 1/2·NCT04145375·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for ZEN003694. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZEN003694 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZEN003694. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zenith Epigenetics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: ZZenith Epigenetics

ZEN003694

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2033

Trials by Indication[1]

Prostate Cancer3 trials

Lung Cancer1 trial

Ovarian Cancer1 trial

Breast Cancer1 trial

Solid Tumors1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News